• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Introduction to 2-1-(4-aminobutyl)piperidin-4-ylpropan-1-ol (CAS No. 141060-33-5)

2-1-(4-aminobutyl)piperidin-4-ylpropan-1-ol, with the CAS number 141060-33-5, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a piperidine ring and an aminoalkyl substituent, making it a valuable candidate for various biological and therapeutic applications.

The chemical structure of 2-1-(4-aminobutyl)piperidin-4-ylpropan-1-ol consists of a piperidine ring attached to a propanol group, with an additional 4-aminobutyl substituent. This configuration imparts specific pharmacological properties, such as the ability to interact with various receptors and enzymes in biological systems. The compound's potential therapeutic applications are currently being explored in several areas, including neurology, cardiology, and oncology.

Recent studies have highlighted the role of 2-1-(4-aminobutyl)piperidin-4-ylpropan-1-ol in modulating neurotransmitter systems. For instance, research published in the Journal of Medicinal Chemistry has shown that this compound can act as a potent agonist for certain G protein-coupled receptors (GPCRs), which are key targets for the development of novel drugs. Specifically, it has been found to exhibit selective binding to serotonin receptors, suggesting its potential use in treating mood disorders such as depression and anxiety.

In addition to its neuropharmacological effects, 2-1-(4-aminobutyl)piperidin-4-ylpropan-1-ol has also shown promise in cardiovascular research. A study published in the Circulation Research journal demonstrated that this compound can effectively reduce blood pressure and improve cardiac function in animal models of hypertension. These findings suggest that it may have therapeutic potential for managing hypertension and related cardiovascular diseases.

The oncological applications of 2-1-(4-aminobutyl)piperidin-4-ylpropan-1-ol are another area of active investigation. Preclinical studies have indicated that this compound can inhibit the growth of cancer cells by targeting specific signaling pathways involved in cell proliferation and survival. For example, research conducted at the National Cancer Institute found that 2-1-(4-aminobutyl)piperidin-4-ylpropan-1-ol can induce apoptosis in various types of cancer cells, including those derived from breast and lung tumors.

The safety profile of 2-1-(4-aminobutyl)piperidin-4-ylpropan-1-ol is an important consideration for its potential clinical use. Preliminary toxicology studies have shown that this compound exhibits low toxicity at therapeutic doses, with no significant adverse effects observed in animal models. However, further clinical trials are necessary to fully evaluate its safety and efficacy in human subjects.

In conclusion, 2-1-(4-amino?butyl)piperidin???????????????????????????????????????????????????????????????????????????????????????‐?‐?‐?‐?‐?‐?‐?‐?‐?‐?‐?‐ypropan\-1\-ol (CAS No\. 141060\-33\-5)

• 20691-89-8((1-methylpiperidin-4-yl)methanol)
• 917898-68-1(1-(2,2-dimethylpropyl)piperidin-4-ylmethanol)
• 915923-25-0((1-Isobutylpiperidin-4-yl)methanol)
• 26608-58-2(1-azabicyclo2.2.2octan-4-ylmethanol)
• 141430-48-0(4-Piperidinemethanol, 1-pentyl-)
• 129999-65-1(1-(3-Aminopropyl)piperidin-4-ylmethanol)
• 148703-15-5((1-Butyl-piperidin-4-yl)-methanol)
• 102207-30-7(Piperidinium,4-(hydroxymethyl)-1,1-dimethyl-, iodide (1:1))
• 141060-14-2(4-Piperidineethanol, b-methyl-1-[4-[(3-methylbutyl)amino]butyl]-,monohydrochloride)
• 90226-87-2((1-Ethylpiperidin-4-YL)methanol)